Neurometrix Inc (NURO) 1.66 $NURO
NeuroMetrix Q4 & FY14 results
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 9:55AM CST
NURO: 1.66 (unch)
NeuroMetrix's (NURO) CEO Dr. Shai Gozani on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 9:12AM CST
NURO: 1.66 (unch)
NeuroMetrix reports Q4 results
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:04AM CST
NURO: 1.66 (unch)
NeuroMetrix Reports Q4 2014 Financial Results and Highlights
Business Wire - Thu Feb 12, 6:00AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2014.
NURO: 1.66 (unch)
Wearable Tech Makes Inroads; Attire's Smart Leap
at Investor's Business Daily - Tue Feb 10, 12:41PM CST
The professional wardrobe is expanding with smart accessories. Here's how to make the most of the advancements: See potential. Workers worldwide are ready to embrace wearable devices, according to a Harris Poll survey, which found that 73% of...
NURO: 1.66 (unch)
NeuroMetrix, Inc. Announces Date for 2014 Full Year and Fourth Quarter Financial Results Conference Call
Business Wire - Thu Feb 05, 12:40PM CST
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2014 full year and fourth quarter financial results before the opening of the market on February 12, 2015. The Company will host a conference call at 8:00 a.m., Eastern Time on February 12, 2015 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.66 (unch)
NeuroMetrix Presents Business Overview at Biotech Showcase 2015
Business Wire - Thu Jan 15, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq:NURO) reported that its President and Chief Executive Officer, Shai N. Gozani, M.D., Ph.D., provided an update and overview of company business activities on January 14, 2015 at the Biotech Showcase 2015 conference in San Francisco. Dr. Gozani's discussion particularly focused on Quell(TM), the company's newly unveiled wearable technology for relief of chronic pain. The presentation is archived and may be accessed for 90 days at http://edge.media-server.com/m/p/audrhjcw. The corporate presentation used by Dr. Gozani is available at www.NeuroMetrix.com under the "Investor Relations" tab.
NURO: 1.66 (unch)
Consumer and Industry Interest High for NeuroMetrix Quell(TM) Wearable Pain Relief Technology
Business Wire - Wed Jan 14, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell coming out of last week's Consumer Electronics Show (CES).
NURO: 1.66 (unch)
NeuroMetrix Quell(TM) Wearable Pain Relief Technology Attracts Broad Attention at International Consumer Electronics Show
Business Wire - Fri Jan 09, 9:56AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Quell has been featured in several forums during this year's International Consumer Electronics Show (CES). Among the highlights:
NURO: 1.66 (unch)
NeuroMetrix Launches Quell(TM) Wearable Pain Relief Technology at 2015 International Consumer Electronics Show to Strong Initial Interest
Business Wire - Wed Jan 07, 9:30AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that industry insiders got their first look at Quell during day 1 of this year's International Consumer Electronics Show (CES).
NURO: 1.66 (unch)
NeuroMetrix to Present at Biotech Showcase 2015
Business Wire - Tue Jan 06, 6:01AM CST
NeuroMetrix, Inc. announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2015 Conference being held in San Francisco, CA. Dr. Gozani intends to provide an overall business update and a discussion on Quell(TM), the Company's over the counter wearable pain relief device recently unveiled at the International Consumer Electronics Show (CES) in Las Vegas. A live audio and slide webcast will be available on the investor relations section of the corporate website - http://www.NeuroMetrix.com/. This webcast will be archived for one month after the live event.
NURO: 1.66 (unch)
NeuroMetrix to debut wearable pain relief device at CES
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 9:38AM CST
NURO: 1.66 (unch)
NeuroMetrix to Showcase Quell(TM) Wearable Pain Relief Technology at the 2015 International Consumer Electronics Show
Business Wire - Mon Dec 29, 8:56AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) will unveil and demonstrate Quell, a novel wearable pain relief device at the 2015 International Consumer Electronics show (CES) January 6-9 in Las Vegas. Attendees will get their first glimpse of Quell at Booth # 73311 in the Digital Health section of CES. NeuroMetrix will also be one of an exclusive group that will participate in CES Unveiled, the official press event of CES.
NURO: 1.66 (unch)
NeuroMetrix Selected to Showcase Quell(TM) Wearable Pain Relief Technology at 2015 CES Unveiled
Business Wire - Tue Dec 16, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will join an exclusive number of companies to participate in CES Unveiled, the official press event of the International Consumer Electronics Show in Las Vegas in January 2015.
NURO: 1.66 (unch)
Natus Medical (BABY) Hits 52-Week High on Bullish Trends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:05PM CST
Shares of Natus Medical Inc. (BABY) scaled a 52-week high of $35.93 on Dec 9 and closed a trifle lower at $35.70, representing a healthy year-to-date return of approximately 58.7%.
JNJ: 99.62 (+1.18), BABY: 36.96 (-0.03), ALOT: 14.65 (+0.53), NURO: 1.66 (unch)
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology
Business Wire - Wed Dec 10, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company's wearable pain relief technology. The patent addresses an important element in the Company proprietary OptiTherapy(TM) technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers the automated calibration procedure that determines the appropriate stimulation level for each device user. The Company expects the patent to issue in mid-2015 and to extend patent protection into 2032. The technology is incorporated in the currently marketed prescription SENSUS(R) pain management device and in Quell(TM) which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.66 (unch)
NeuroMetrix to Participate in the Benchmark Micro Cap Discovery Conference
Business Wire - Mon Dec 08, 11:59AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the one-on-one Benchmark Micro Cap Discovery Conference which will be held at the Palmer House Hilton, Chicago, IL on Thursday, December 11, 2014 from 8:00am to 2:30pm. Dr. Gozani intends to provide a business update and discuss development progress on Quell(TM), the Company's over the counter wearable pain relief device which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015. To schedule a one-on-one meeting with Dr. Gozani please e-mail vcuratola@benchmarkcompany.com or contact your Benchmark representative.
NURO: 1.66 (unch)
NeuroMetrix to Unveil Revolutionary Wearable Pain Relief Device at 2015 International Consumer Electronics Show
Business Wire - Wed Nov 19, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil Quell(TM), the Company's wearable pain relief device at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.66 (unch)
NeuroMetrix ups revenues 8% in Q3
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:44PM CDT
NURO: 1.66 (unch)
NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 10:31AM CDT
NURO: 1.66 (unch)
NeuroMetrix Q4 & FY14 results
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 9:55AM CST
NURO: 1.66 (unch)
NeuroMetrix's (NURO) CEO Dr. Shai Gozani on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 9:12AM CST
NURO: 1.66 (unch)
NeuroMetrix reports Q4 results
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:04AM CST
NURO: 1.66 (unch)
NeuroMetrix Reports Q4 2014 Financial Results and Highlights
Business Wire - Thu Feb 12, 6:00AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2014. NURO: 1.66 (unch)
Wearable Tech Makes Inroads; Attire's Smart Leap
at Investor's Business Daily - Tue Feb 10, 12:41PM CST
The professional wardrobe is expanding with smart accessories. Here's how to make the most of the advancements: See potential. Workers worldwide are ready to embrace wearable devices, according to a Harris Poll survey, which found that 73% of...
NURO: 1.66 (unch)
NeuroMetrix, Inc. Announces Date for 2014 Full Year and Fourth Quarter Financial Results Conference Call
Business Wire - Thu Feb 05, 12:40PM CST
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2014 full year and fourth quarter financial results before the opening of the market on February 12, 2015. The Company will host a conference call at 8:00 a.m., Eastern Time on February 12, 2015 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.66 (unch)
NeuroMetrix Presents Business Overview at Biotech Showcase 2015
Business Wire - Thu Jan 15, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq:NURO) reported that its President and Chief Executive Officer, Shai N. Gozani, M.D., Ph.D., provided an update and overview of company business activities on January 14, 2015 at the Biotech Showcase 2015 conference in San Francisco. Dr. Gozani's discussion particularly focused on Quell(TM), the company's newly unveiled wearable technology for relief of chronic pain. The presentation is archived and may be accessed for 90 days at http://edge.media-server.com/m/p/audrhjcw. The corporate presentation used by Dr. Gozani is available at www.NeuroMetrix.com under the "Investor Relations" tab.
NURO: 1.66 (unch)
Consumer and Industry Interest High for NeuroMetrix Quell(TM) Wearable Pain Relief Technology
Business Wire - Wed Jan 14, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell coming out of last week's Consumer Electronics Show (CES).
NURO: 1.66 (unch)
NeuroMetrix Quell(TM) Wearable Pain Relief Technology Attracts Broad Attention at International Consumer Electronics Show
Business Wire - Fri Jan 09, 9:56AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Quell has been featured in several forums during this year's International Consumer Electronics Show (CES). Among the highlights:
NURO: 1.66 (unch)
NeuroMetrix Launches Quell(TM) Wearable Pain Relief Technology at 2015 International Consumer Electronics Show to Strong Initial Interest
Business Wire - Wed Jan 07, 9:30AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that industry insiders got their first look at Quell during day 1 of this year's International Consumer Electronics Show (CES).
NURO: 1.66 (unch)
NeuroMetrix to Present at Biotech Showcase 2015
Business Wire - Tue Jan 06, 6:01AM CST
NeuroMetrix, Inc. announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2015 Conference being held in San Francisco, CA. Dr. Gozani intends to provide an overall business update and a discussion on Quell(TM), the Company's over the counter wearable pain relief device recently unveiled at the International Consumer Electronics Show (CES) in Las Vegas. A live audio and slide webcast will be available on the investor relations section of the corporate website - http://www.NeuroMetrix.com/. This webcast will be archived for one month after the live event.
NURO: 1.66 (unch)
NeuroMetrix to debut wearable pain relief device at CES
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 9:38AM CST
NURO: 1.66 (unch)
NeuroMetrix to Showcase Quell(TM) Wearable Pain Relief Technology at the 2015 International Consumer Electronics Show
Business Wire - Mon Dec 29, 8:56AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) will unveil and demonstrate Quell, a novel wearable pain relief device at the 2015 International Consumer Electronics show (CES) January 6-9 in Las Vegas. Attendees will get their first glimpse of Quell at Booth # 73311 in the Digital Health section of CES. NeuroMetrix will also be one of an exclusive group that will participate in CES Unveiled, the official press event of CES.
NURO: 1.66 (unch)
NeuroMetrix Selected to Showcase Quell(TM) Wearable Pain Relief Technology at 2015 CES Unveiled
Business Wire - Tue Dec 16, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will join an exclusive number of companies to participate in CES Unveiled, the official press event of the International Consumer Electronics Show in Las Vegas in January 2015.
NURO: 1.66 (unch)
Natus Medical (BABY) Hits 52-Week High on Bullish Trends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:05PM CST
Shares of Natus Medical Inc. (BABY) scaled a 52-week high of $35.93 on Dec 9 and closed a trifle lower at $35.70, representing a healthy year-to-date return of approximately 58.7%.
JNJ: 99.62 (+1.18), BABY: 36.96 (-0.03), ALOT: 14.65 (+0.53), NURO: 1.66 (unch)
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology
Business Wire - Wed Dec 10, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company's wearable pain relief technology. The patent addresses an important element in the Company proprietary OptiTherapy(TM) technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers the automated calibration procedure that determines the appropriate stimulation level for each device user. The Company expects the patent to issue in mid-2015 and to extend patent protection into 2032. The technology is incorporated in the currently marketed prescription SENSUS(R) pain management device and in Quell(TM) which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.66 (unch)
NeuroMetrix to Participate in the Benchmark Micro Cap Discovery Conference
Business Wire - Mon Dec 08, 11:59AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the one-on-one Benchmark Micro Cap Discovery Conference which will be held at the Palmer House Hilton, Chicago, IL on Thursday, December 11, 2014 from 8:00am to 2:30pm. Dr. Gozani intends to provide a business update and discuss development progress on Quell(TM), the Company's over the counter wearable pain relief device which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015. To schedule a one-on-one meeting with Dr. Gozani please e-mail vcuratola@benchmarkcompany.com or contact your Benchmark representative.
NURO: 1.66 (unch)
NeuroMetrix to Unveil Revolutionary Wearable Pain Relief Device at 2015 International Consumer Electronics Show
Business Wire - Wed Nov 19, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil Quell(TM), the Company's wearable pain relief device at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.66 (unch)
NeuroMetrix ups revenues 8% in Q3
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:44PM CDT
NURO: 1.66 (unch)
NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 10:31AM CDT
NURO: 1.66 (unch)
